Retro develops therapies for diseases driven by the biology of aging. We focus on cellular reprogramming and autophagy to rejuvenate cell and tissue function with the ultimate aim of adding 10 years to healthy human lifespan. We are building a mission-driven, collaborative team operating with speed, transparency, and adaptability. We are hiring a new member of the team who will lead analytical development and product quality strategy for RTR242, a small molecule in Phase I for the treatment of neurodegenerative diseases such as Alzheimer’s. In this role, you will provide hands-on leadership for analytical development while owning the end-to-end product quality strategy across CMC, manufacturing, and QC. You will work with our CDMO and CRO partners to achieve quality standards appropriate to stage and intended use.